Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PorphyChem is a French biotechnology company specializing in the design, synthesis, and development of high-purity porphyrins, phthalocyanines, and other macrocyclic compounds. Founded as a spin-off from the University of Burgundy, the company provides a wide range of specialized molecules for applications in photodynamic therapy (PDT), photodynamic inactivation (PDI), and medical imaging. In addition to its extensive product catalog, PorphyChem offers custom synthesis and R&D services to support pharmaceutical and academic partners in developing light-activated therapies. Their expertise spans from molecular design to the production of photosensitizers used in oncology, dermatology, and anti-infectives. The company serves a global market, providing critical chemical building blocks for advanced research in the life sciences and materials science.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PorphyChem.